ADI PEG20

08/01/2010 - "Since both HIF-1α and c-Myc play important roles in cancer cell energy metabolism, together these results suggest that targeted cancer cell metabolism through modulation of HIF-1α and c-Myc expression may improve the efficacy of ADI-PEG20 in treating Arg auxotrophic tumors."
01/01/2020 - "We also evaluated the efficacy of PAN and ADI-PEG20 (an Arg-degrading agent currently in Phase 2 clinical trials) in xenograft models with ASS1-low and -high PDAC tumors. "
01/01/2023 - "This study examines the role of ASS1 silencing on tumor growth and initiation and identifies a noncanonical mechanism of resistance, aiming to improve clinical responses to ADI-PEG20. "
01/01/2023 - "Noncanonical, ASS1-independent tumor resistance to ADI-PEG20 is driven by the microenvironment. "
06/14/2020 - "Unfortunately, ASS-positive cancers are resistant to ADI-PEG20. "

04/01/2013 - "Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma."
08/01/2010 - "Clinical studies in melanoma patients show that re-expression of ASS is associated with ADI-PEG20 resistance. "
10/20/2005 - "Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies."
07/16/2021 - "The combination of TRAIL and ADI-PEG20 as one example can greatly enhance the cytotoxicity to melanoma cells including those resistant to the single component of this combination. "
04/24/2012 - "ADI-PEG20 is safe and the drug is only efficacious in melanoma patients whose tumour has negative ASS expression. "

08/01/2015 - "Treatment with pegylated arginine deiminase (ADI-PEG 20) selectively eliminates arginine from the circulation and has shown some efficacy against ASS-deficient tumors including small cell lung cancer (SCLC). "
11/01/2020 - "Pre-clinical studies indicated that arginine-deprivation therapy using pegylated arginine deiminase (pegargiminase, ADI-PEG 20) may be effective in patients with argininosuccinate synthetase 1 (ASS1)-deficient small-cell lung cancer (SCLC). "
01/01/2022 - "Small cell lung cancer (SCLC) displays marked arginine auxotrophy due to inactivation of the rate-limiting enzyme argininosuccinate synthetase 1 (ASS1), and as a consequence may be targeted with pegylated arginine deiminase or ADI-PEG20 (pegargiminase) and human recombinant pegylated arginases (rhArgPEG, BCT-100 and pegzilarginase). "

01/01/2017 - "In this trial, arginine deprivation with ADI-PEG20 improved PFS in patients with ASS1-deficient mesothelioma. "
06/01/2023 - "A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma."
06/01/2023 - "Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma."
03/01/2013 - "Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase."

01/15/2009 - "Finally, a tissue microarray of 88 prostate tumor samples lacked expression of ASS, indicating ADI-PEG20 is a potential novel therapy for the treatment of prostate cancer"
11/02/2010 - "Recent studies showed that a combination of taxane and ADI-PEG20, which induces caspase-independent apoptosis, is more effective than taxane monotherapy for prostate cancer. "
01/15/2009 - "CWR22Rv1 prostate cancer cells do not express ASS, the rate-limiting enzyme in arginine synthesis, and are susceptible to ADI-PEG20 in vitro. "